Company news

Phathom Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Phathom Pharmaceuticals Announces Revenue Interest Financing Agreement for Up to $260 Million in Non-Dilutive Capital

May 3, 2022

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults

May 2, 2022

Phathom Pharmaceuticals Appoints Frank Karbe to its Board of Directors

April 25, 2022

Phathom Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference

March 31, 2022

Phathom Pharmaceuticals Announces Appointment of Molly Henderson as Chief Financial and Business Officer

March 21, 2022

Phathom Pharmaceuticals Submits Vonoprazan NDA to FDA for the Treatment of Erosive Esophagitis

March 13, 2022

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Pipeline and Business Progress

February 28, 2022

Phathom Pharmaceuticals Announces Positive Topline Results from Phase 2 Trial Evaluating Vonoprazan for Non-Erosive Gastroesophageal Reflux Disease (NERD)

February 8, 2022

Phathom Pharmaceuticals to Participate in the 4th Annual Evercore ISI HealthCONx Conference

November 22, 2021

Phathom Pharmaceuticals to Participate in Two Upcoming Investor Healthcare Conferences

November 11, 2021

Phathom Pharmaceuticals Reports Third Quarter 2021 Results and Provides Key Clinical, Regulatory, and Business Updates

November 7, 2021

Phathom Pharmaceuticals Withdraws Public Offering

October 26, 2021

Phathom Pharmaceuticals Announces Proposed Public Offering of 5,000,000 Shares of Common Stock

October 25, 2021

Phathom Pharmaceuticals Announces New Data at ACG 2021 Annual Scientific Meeting

October 23, 2021

Phathom Pharmaceuticals to Present New Data at ACG 2021 Annual Scientific Meeting

October 20, 2021

Phathom Pharmaceuticals Announces Positive Topline Results from PHALCON-EE Pivotal Phase 3 Erosive Esophagitis Trial

October 17, 2021

Phathom Pharmaceuticals Announces Results from VONO-103, a Phase 1 Study Evaluating Gastric Acid Inhibition of Vonoprazan and Lansoprazole (PREVACID®)

September 26, 2021

Phathom Pharmaceuticals Secures $200 Million Term Loan Facility from Hercules Capital

September 19, 2021

Phathom Pharmaceuticals Submits Two NDAs to U.S. FDA for Vonoprazan-based Treatment Regimens for the Treatment of H. pylori Infection

September 7, 2021

Phathom Pharmaceuticals to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

August 30, 2021

Phathom Pharmaceuticals Reports Second Quarter 2021 Results and Provides Update Regarding Key Clinical and Regulatory Milestones

August 9, 2021

Phathom Pharmaceuticals Mourns the Loss of Chairman and Founder, Tadataka "Tachi" Yamada, M.D.

August 4, 2021

Phathom Pharmaceuticals to Participate in the BMO Biopharma Spotlight Series: Innovation in GI

August 1, 2021

Phathom Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

May 24, 2021

Phathom Pharmaceuticals Reports First Quarter 2021 Results and Provides Recent Business Updates

May 10, 2021

Phathom Pharmaceuticals to Present at the Bank of America Securities 2021 Virtual Healthcare Conference

May 5, 2021

Phathom Pharmaceuticals Announces Positive Topline Results from Pivotal Phase 3 Trial of Vonoprazan in Helicobacter pylori (H. pylori) Infection; Study Met All Primary and Secondary Endpoints

April 28, 2021

Phathom Pharmaceuticals to Present at 20th Annual Needham Virtual Healthcare Conference

April 5, 2021

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Pipeline and Business Progress

March 29, 2021

Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) Trial

January 18, 2021

Phathom Pharmaceuticals Announces Proposed Public Offering of 2,250,000 Shares of Common Stock

December 14, 2020

Phathom Pharmaceuticals Announces Plans to Initiate Vonoprazan Development Program in Non-Erosive Reflux Disease (NERD)

December 13, 2020

Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Erosive Esophagitis Trial

November 29, 2020

Phathom Pharmaceuticals to Participate at Upcoming Investor Healthcare Conferences

November 26, 2020

Phathom Pharmaceuticals to Host Virtual Investor Day

November 18, 2020

Phathom Pharmaceuticals to Present at the Jefferies Virtual London Healthcare Conference

November 12, 2020

Phathom Pharmaceuticals Reports Third Quarter 2020 Results and Provides Update on Phase 3 Trials

November 9, 2020

Phathom Pharmaceuticals to Present at Morgan Stanley 18th Annual Global Healthcare Conference

September 8, 2020

Phathom Pharmaceuticals Reports Second Quarter 2020 Results

August 5, 2020

Phathom Pharmaceuticals Announces Appointment of Todd Branning as Chief Financial Officer

July 12, 2020

Phathom Pharmaceuticals Provides Clinical Trial Status Update

June 14, 2020

Phathom Pharmaceuticals to Present at Upcoming Investor Conferences

May 27, 2020

Phathom Pharmaceuticals Reports First Quarter 2020 Results

May 11, 2020

Phathom to Participate at the 19th Annual Needham Virtual Healthcare Conference

April 8, 2020

Phathom Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Clinical Trial Status and Business Updates

March 18, 2020

Phathom Pharmaceuticals to Present at 40th Annual Cowen and Company Health Care Conference on March 2, 2020

February 24, 2020

Phathom Pharmaceuticals Appoints Martin J. Gilligan as Chief Commercial Officer

January 5, 2020

Phathom Pharmaceuticals Announces Initiation of Pivotal Phase 3 Clinical Trial for Vonoprazan in Helicobacter Pylori (H. pylori) Infection

December 22, 2019

Phathom Pharmaceuticals Expands Leadership Team and Announces Board Transition

December 1, 2019

Phathom Pharmaceuticals Announces Initiation of Pivotal Phase 3 Clinical Trial for Vonoprazan in Erosive Esophagitis

December 1, 2019

← Newer news releases · Older news releases →

Calls

The 5 newest of 12 calls. Every call is listed under its year.

Decks

The 5 newest of 14 decks. Every deck is listed under its year.